Anti – HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140 , a CCR 5 Monoclonal Antibody

Jeffrey M. Jacobson, Melanie A. Thompson, Jacob P. Lalezari, Michael S. Saag, Barry S. Zingman, Paul D’Ambrosio, Nancy Stambler, Yakov Rotshteyn, Andre J. Marozsan, Paul J. Maddon, Stephen A. Morris, and William C. Olson Drexel University College of Medicine, Philadelphia, Pennsylvania; AIDS Research Consortium of Atlanta, Atlanta, Georgia; Quest Clinical Research, San Francisco, California; University of Alabama, Birmingham; Montefiore Medical Center and Einstein/Montefiore Center for AIDS Research, Bronx, and Progenics Pharmaceuticals, Tarrytown, New York

[1]  James Theiler,et al.  Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo , 2009, PloS one.

[2]  John P. Moore,et al.  A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors , 2009, Current opinion in HIV and AIDS.

[3]  R. Redfield,et al.  Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. , 2008, The Journal of infectious diseases.

[4]  A. Marozsan.  Clonal Analysis of HIV-1 Co-receptor Tropism Change Following Treatment with PRO 140, a CCR5 Monoclonal Antibody , 2008 .

[5]  Anders Karlsson,et al.  Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.

[6]  B. Clotet,et al.  Variability in the Plasma Concentration of Efavirenz and Nevirapine is Associated with Genotypic Resistance after Treatment Interruption , 2008, Antiviral therapy.

[7]  B G Gazzard,et al.  Switching from twice‐daily abacavir and lamivudine to the once‐daily fixed‐dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy , 2008, HIV medicine.

[8]  J. Halter,et al.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Anne M Johnson,et al.  Changes in the risk of death after HIV seroconversion compared with mortality in the general population. , 2008, JAMA.

[10]  M. Witt,et al.  Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral Suppression , 2008, HIV clinical trials.

[11]  M. Johnson,et al.  A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. , 2007, AIDS research and human retroviruses.

[12]  B. Chi,et al.  Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial , 2007, The Lancet.

[13]  Justin C McArthur,et al.  The prevalence and incidence of neurocognitive impairment in the HAART era , 2007, AIDS.

[14]  F. Raffi,et al.  Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults , 2007, AIDS.

[15]  D. Kuritzkes,et al.  Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. , 2007, The Journal of infectious diseases.

[16]  Eoin Coakley,et al.  HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  P. Tebas,et al.  Cardiovascular risks of antiretroviral therapies. , 2007, Annual review of medicine.

[18]  M. Franti,et al.  Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1 , 2006, Antimicrobial Agents and Chemotherapy.

[19]  O. Kirk,et al.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.

[20]  M. Lederman,et al.  Biology of CCR5 and its role in HIV infection and treatment. , 2006, JAMA.

[21]  H. Ochs,et al.  Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases , 2006, Journal of Clinical Immunology.

[22]  Mike Youle,et al.  Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir , 2006, Journal of Virology.

[23]  Michael S Saag,et al.  Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 , 2005, Nature Medicine.

[24]  R. Davey,et al.  Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults , 2005, AIDS.

[25]  P. Harrigan,et al.  Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. , 2005, The Journal of infectious diseases.

[26]  B. Gazzard,et al.  Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.

[27]  D. Dimitrov,et al.  Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy , 2001, The Lancet.

[28]  C. Porter,et al.  Transport and absorption of drugs via the lymphatic system. , 2001, Advanced drug delivery reviews.

[29]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[30]  W. Heneine,et al.  Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma. , 1999, AIDS research and human retroviruses.

[31]  D. Richman,et al.  Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.

[32]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[33]  L. Hammarström,et al.  Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs , 1995, The Lancet.

[34]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[35]  Michael S. Saag,et al.  A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1993 .

[36]  B. Thiers.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2009 .

[37]  S. Hammer,et al.  Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society–USA Panel , 2008 .

[38]  J. Kappes,et al.  A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. , 1993, The New England journal of medicine.